INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
Public company

BCAXBicara Therapeutics Inc.

CIK 0002023658

EDGAR filingsOpen in network
Disclosed transactions50
Buys / sells0 / 16
Max Insider Score30
Connections5with evidence

BCAX · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
0
HI
Hyep IvanChief Financial Officer
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M$35K
9,200 sh
Apr 21, 2026Apr 22, 2026
traded Apr 21, 2026
+1dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Cohlhepp RyanDirector, President and COO · Nov 25, 2025
  • ← Insider ofevidence
    Mazumdar ClaireDirector, Chief Executive Officer · Nov 25, 2025
  • ← Insider ofevidence
    Raben DavidChief Medical Officer · Nov 25, 2025
3
HI
Hyep IvanChief Financial Officer
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M
—
9,200 sh
Apr 21, 2026
Apr 22, 2026
traded Apr 21, 2026
+1d
SEC FORM 4

Evidence

13
HI
Hyep IvanChief Financial Officer
BCAXBicara Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$212K
9,200 sh
Apr 21, 2026Apr 22, 2026
traded Apr 21, 2026
+1dSEC FORM 4

Evidence

0
MC
Mazumdar ClaireDirector, Chief Executive Officer
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M$36K
8,226 sh
Apr 16, 2026Apr 20, 2026
traded Apr 16, 2026
+4dSEC FORM 4

Evidence

0
MC
Mazumdar ClaireDirector, Chief Executive Officer
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M—
15.0K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

0
MC
Mazumdar ClaireDirector, Chief Executive Officer
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M—
7,080 sh
Apr 16, 2026Apr 20, 2026
traded Apr 16, 2026
+4dSEC FORM 4

Evidence

0
MC
Mazumdar ClaireDirector, Chief Executive Officer
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M—
7,454 sh
Apr 16, 2026Apr 20, 2026
traded Apr 16, 2026
+4dSEC FORM 4

Evidence

0
MC
Mazumdar ClaireDirector, Chief Executive Officer
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M—
8,226 sh
Apr 16, 2026Apr 20, 2026
traded Apr 16, 2026
+4dSEC FORM 4

Evidence

12
MC
Mazumdar ClaireDirector, Chief Executive Officer
BCAXBicara Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$354K
15.0K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

0
MC
Mazumdar ClaireDirector, Chief Executive Officer
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M$57K
15.0K sh
Apr 20, 2026Apr 20, 2026
traded Apr 20, 2026
+0dSEC FORM 4

Evidence

0
MC
Mazumdar ClaireDirector, Chief Executive Officer
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M$39K
7,080 sh
Apr 16, 2026Apr 20, 2026
traded Apr 16, 2026
+4dSEC FORM 4

Evidence

0
MC
Mazumdar ClaireDirector, Chief Executive Officer
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M$28K
7,454 sh
Apr 16, 2026Apr 20, 2026
traded Apr 16, 2026
+4dSEC FORM 4

Evidence

0
RD
Raben DavidChief Medical Officer
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M$21K
5,500 sh
Mar 25, 2026Mar 26, 2026
traded Mar 25, 2026
+1dSEC FORM 4

Evidence

0
RD
Raben DavidChief Medical Officer
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M—
5,500 sh
Mar 25, 2026Mar 26, 2026
traded Mar 25, 2026
+1dSEC FORM 4

Evidence

8
RD
Raben DavidChief Medical Officer
BCAXBicara Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$104K
5,500 sh
Mar 25, 2026Mar 26, 2026
traded Mar 25, 2026
+1dSEC FORM 4

Evidence

9
CR
Cohlhepp RyanDirector, President and COO
BCAXBicara Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$69K
3,828 sh
Jan 22, 2026Jan 26, 2026
traded Jan 22, 2026
+4dSEC FORM 4

Evidence

0
HI
Hyep IvanChief Financial Officer
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M—
1,882 sh
Jan 22, 2026Jan 26, 2026
traded Jan 22, 2026
+4dSEC FORM 4

Evidence

6
HI
Hyep IvanChief Financial Officer
BCAXBicara Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$34K
1,882 sh
Jan 22, 2026Jan 26, 2026
traded Jan 22, 2026
+4dSEC FORM 4

Evidence

0
HI
Hyep IvanChief Financial Officer
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M$7,132
1,882 sh
Jan 22, 2026Jan 26, 2026
traded Jan 22, 2026
+4dSEC FORM 4

Evidence

0
HI
Hyep IvanChief Financial Officer
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M—
9,200 sh
Dec 22, 2025Dec 23, 2025
traded Dec 22, 2025
+1dSEC FORM 4

Evidence

13
HI
Hyep IvanChief Financial Officer
BCAXBicara Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$168K
9,200 sh
Dec 22, 2025Dec 23, 2025
traded Dec 22, 2025
+1dSEC FORM 4

Evidence

0
HI
Hyep IvanChief Financial Officer
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M$35K
9,200 sh
Dec 22, 2025Dec 23, 2025
traded Dec 22, 2025
+1dSEC FORM 4

Evidence

12
MC
Mazumdar ClaireDirector, Chief Executive Officer
BCAXBicara Therapeutics Inc.
Option exercise
M$161K
29.5K sh
Dec 16, 2025Dec 18, 2025
traded Dec 16, 2025
+2dSEC FORM 4

Evidence

9
MC
Mazumdar ClaireDirector, Chief Executive Officer
BCAXBicara Therapeutics Inc.
Option exercise
M—
29.5K sh
Dec 16, 2025Dec 18, 2025
traded Dec 16, 2025
+2dSEC FORM 4

Evidence

9
CR
Cohlhepp RyanDirector, President and COO
BCAXBicara Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$149K
8,000 sh
Dec 15, 2025Dec 16, 2025
traded Dec 15, 2025
+1dSEC FORM 4

Evidence

0
CR
Cohlhepp RyanDirector, President and COO
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M$30K
8,000 sh
Dec 15, 2025Dec 16, 2025
traded Dec 15, 2025
+1dSEC FORM 4

Evidence

9
CR
Cohlhepp RyanDirector, President and COO
BCAXBicara Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$84K
4,500 sh
Dec 15, 2025Dec 16, 2025
traded Dec 15, 2025
+1dSEC FORM 4

Evidence

0
CR
Cohlhepp RyanDirector, President and COO
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M—
8,000 sh
Dec 15, 2025Dec 16, 2025
traded Dec 15, 2025
+1dSEC FORM 4

Evidence

23
CR
Cohlhepp RyanDirector, President and COO
BCAXBicara Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$144K
8,000 sh
Nov 21, 2025Nov 25, 2025
traded Nov 21, 2025
+4dSEC FORM 4

Evidence

23
CR
Cohlhepp RyanDirector, President and COO
BCAXBicara Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$81K
4,500 sh
Nov 21, 2025Nov 25, 2025
traded Nov 21, 2025
+4dSEC FORM 4

Evidence

3
CR
Cohlhepp RyanDirector, President and COO
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M—
8,000 sh
Nov 21, 2025Nov 25, 2025
traded Nov 21, 2025
+4dSEC FORM 4

Evidence

0
CR
Cohlhepp RyanDirector, President and COO
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M$30K
8,000 sh
Nov 21, 2025Nov 25, 2025
traded Nov 21, 2025
+4dSEC FORM 4

Evidence

3
HI
Hyep IvanChief Financial Officer
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M—
17.8K sh
Nov 24, 2025Nov 25, 2025
traded Nov 24, 2025
+1dSEC FORM 4

Evidence

0
HI
Hyep IvanChief Financial Officer
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M—
605 sh
Nov 21, 2025Nov 25, 2025
traded Nov 21, 2025
+4dSEC FORM 4

Evidence

26
HI
Hyep IvanChief Financial Officer
BCAXBicara Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$330K
17.8K sh
Nov 24, 2025Nov 25, 2025
traded Nov 24, 2025
+1dSEC FORM 4

Evidence

2
HI
Hyep IvanChief Financial Officer
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M$67K
17.8K sh
Nov 24, 2025Nov 25, 2025
traded Nov 24, 2025
+1dSEC FORM 4

Evidence

20
HI
Hyep IvanChief Financial Officer
BCAXBicara Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$11K
605 sh
Nov 21, 2025Nov 25, 2025
traded Nov 21, 2025
+4dSEC FORM 4

Evidence

0
HI
Hyep IvanChief Financial Officer
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M$2,293
605 sh
Nov 21, 2025Nov 25, 2025
traded Nov 21, 2025
+4dSEC FORM 4

Evidence

0
RD
Raben DavidChief Medical Officer
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M—
906 sh
Nov 25, 2025Nov 25, 2025
traded Nov 25, 2025
+0dSEC FORM 4

Evidence

0
RD
Raben DavidChief Medical Officer
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M—
4,594 sh
Nov 25, 2025Nov 25, 2025
traded Nov 25, 2025
+0dSEC FORM 4

Evidence

0
RD
Raben DavidChief Medical Officer
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M—
5,500 sh
Nov 24, 2025Nov 25, 2025
traded Nov 24, 2025
+1dSEC FORM 4

Evidence

16
RD
Raben DavidChief Medical Officer
BCAXBicara Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$17K
906 sh
Nov 25, 2025Nov 25, 2025
traded Nov 25, 2025
+0dSEC FORM 4

Evidence

0
RD
Raben DavidChief Medical Officer
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M$3,434
906 sh
Nov 25, 2025Nov 25, 2025
traded Nov 25, 2025
+0dSEC FORM 4

Evidence

23
RD
Raben DavidChief Medical Officer
BCAXBicara Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$87K
4,594 sh
Nov 25, 2025Nov 25, 2025
traded Nov 25, 2025
+0dSEC FORM 4

Evidence

0
RD
Raben DavidChief Medical Officer
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M$17K
4,594 sh
Nov 25, 2025Nov 25, 2025
traded Nov 25, 2025
+0dSEC FORM 4

Evidence

27
RD
Raben DavidChief Medical Officer
BCAXBicara Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$101K
5,500 sh
Nov 24, 2025Nov 25, 2025
traded Nov 24, 2025
+1dSEC FORM 4

Evidence

3
RD
Raben DavidChief Medical Officer
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M$21K
5,500 sh
Nov 24, 2025Nov 25, 2025
traded Nov 24, 2025
+1dSEC FORM 4

Evidence

7
MC
Mazumdar ClaireDirector, Chief Executive Officer
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M—
41.2K sh
Nov 24, 2025Nov 25, 2025
traded Nov 24, 2025
+1dSEC FORM 4

Evidence

30
MC
Mazumdar ClaireDirector, Chief Executive Officer
BCAXBicara Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$776K
41.2K sh
Nov 24, 2025Nov 25, 2025
traded Nov 24, 2025
+1dSEC FORM 4

Evidence

6
MC
Mazumdar ClaireDirector, Chief Executive Officer
BCAXBicara Therapeutics Inc.
Option exercise · 10b5-1 plan
M$156K
41.2K sh
Nov 24, 2025Nov 25, 2025
traded Nov 24, 2025
+1dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Hyep IvanChief Financial Officer · Nov 25, 2025